anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide an antitumor agent containing hot-water extract of FUKUROTAKE (Volvariella volvacea) as an active component. CONSTITUTION:FUKUROTAKE (fruit body or mycelia) is crushed and preliminarily extracted with a phosphate buffer solution at or below room temperature to remove foreign materials. The unextracted component containing the objective antitumor substance is separated by filtration or centrifugal separation, etc., and extracted with hot water. The amount of water used in the extraction process is 1-1,000pts., preferably 5-100pts. per 1pt. of the FUKUROTAKE and the extraction is carried out at 50-150 deg.C, preferably 80-100 deg.C for 20 min-20hr. The hot-water extraction is repeated 1-10 times, the extracted liquid is separated by filtration or centrifugal separation and the residue is added with water of the aforementioned amount and subjected to repeated extraction. The product is concentrated to obtain the objective antitumor substance. The agent can be administered by oral administration or intravenous injection.
In this randomized, open-label, multicenter clinical trial, we aim to compare the efficacy and safety of intrathecal pemetrexed combined with concomitant involved-field radiation therapy and intrathecal pemetrexed alone for leptomeningeal metastasis patients from solid tumor. Patients were randomly divided into two arms willing to receive involved-field radiation therapy combined with concurrent intrathecal pemetrexed and intrathecal pemetrexed alone, respectively. In concomitant therapy group, participants received induction intrathecal pemetrexed first. Then concomitant intrathecal pemetrexed and involved-field radiation therapy were given. In intrathecal pemetrexed alone group, participants received induction intrathecal pemetrexed and consolidation intrathecal pemetrexed. Pemetrexed was administrated by intrathecal injection via intraventricular administration or lumbar puncture. Induction intrathecal pemetrexed was given twice per week for 2 weeks to all participants first. Then consolidation/concomitant intrathecal pemetrexed was given once per week for 4 weeks. Involved-field radiation therapy was administrated with a total dose of 40 Gy in 20 fractions for 4 weeks to the concomitant therapy group participants. Primary endpoints were clinical response and treatment-related adverse events. Secondary endpoints were overall survival and neurological progression-free survival.
No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay \>72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
Chronic wounds are susceptible to bacterial infections and at high risk of developing antibiotic-resistant bacterial infections. Silver is an antimicrobial by targeting almost all types of bacteria in chronic wounds to reduce the bacterial load in the infected area and further facilitate the healing process. This study focused on exploring whether silver-based dressings were superior to non-silver dressings in the treatment of chronic wounds. PubMed, Web of Science and Embase were comprehensively searched from inception to March 2024 for randomized clinical trials and observational studies. The endpoints in terms of wound healing rate, complete healing time, reduction on wound surface area and wound infection rate were analysed using Review Manager 5.4 software. A total of 15 studies involving 5046 patients were eventually included. The results showed that compared with patients provided with non-silver dressings, patients provided with silver-based dressings had higher wound healing rate (OR: 1.43, 95% CI: 1.10-1.85, p = 0.008), shorter complete healing time (MD: -0.96, 95% CI: -1.08 ~ -0.85, p < 0.00001) and lower wound infection rate (OR: 0.56, 95% CI: 0.40-0.79, p = 0.001); no significant difference in the reduction on wound surface area (MD: 12.41, 95% CI: -19.59-44.40, p = 0.45) was found. These findings suggested that the silver-based dressings were able to enhance chronic wound healing rate, shorten the complete healing time and reduce wound infection rate, but had no significant improvement in the reduction on wound surface area. Large-scale and rigorous studies are required to confirm the beneficial effects of silver-based dressings on chronic wound healing.
FIELD: veterinary science. SUBSTANCE: invention proposes a preparation that can be used for treatment of animals with sicknesses of bacterial etiology - in young stock of cattle and sheep and goats, pigs, horses, poultry, dogs and cats. Preparation has the following components, g: sulfanilamide, 5.0-20.0; trimethoprim, 1.0-4.0; tetracycline antibiotic, 2.5-7.5; and a filling agent, up to 100. Administrated preparation is absorbed from gastroenteric tract into blood and penetrates in all organs and tissues of animal where it occurs for 24 h. The preparation is used for treatment of animals with sicknesses of bacterial etiology. EFFECT: enhanced effectiveness of treatment, decreased treatment amount of animal. 2 cl
The invention belongs to the field of medicines, and discloses a pharmaceutical composition used for treating cardiovascular and cerebrovascular diseases. According to the pharmaceutical composition provided by the invention, prasugrel or a pharmaceutically acceptable salt thereof, and rosuvastatin or a pharmaceutically acceptable salt thereof are adopted as pharmaceutically active ingredients. Rosuvastatin or the pharmaceutically acceptable salt thereof is calculated according to rosuvastatin, and prasugrel or the pharmaceutically acceptable salt thereof is calculated according to prasugrel. In the pharmaceutical composition, the weight ratio of rosuvastatin to prasugrel is 1:0.01-100, and preferably 1:0.2-20. When the pharmaceutical composition is applied in treating cardiovascular and cerebrovascular diseases, the effect is comprehensive, the toxic and side effects are low, and patient compliance can be improved. Therefore, the pharmaceutical composition has good medical application prospect.
A venous positioning projector includes an infrared light source module, a beam splitting element, an infrared light image capturing module, a processor and a visible light projection module. The infrared light source module outputs a first infrared light to the target surface. The infrared light image capturing module includes a filter and an infrared light image capturing element. The beam splitting element transmits a second infrared light reflected by the target surface to the filter. The infrared light image capturing element receives the second infrared light passing through the filter. The processor generates vein image data according to the second infrared light received by the infrared light image capturing element and the first infrared light. The visible light projection module generates visible light according to the vein image data. The visible light is transmitted to the target surface via the beam splitting element to generate a vein image.
Photothermal therapy (PTT) holds considerable clinical promise. However, insufficient PTT-induced tumor recurrence and metastasis is an urgent practical problem that needs to be solved. Herein, a biomimetic mesoporous organosilicon nano-system called PSAB is designed to precisely deplete cancer stem cells (CSCs) and prevent tumor recurrence and metastasis after PTT. The PSAB system is made up of Aggregation-induced emission (AIE)-active photothermal agent, 2TT-oC26B, and SO2 prodrug, benzothiazole sulfinate (BTS), within mesoporous organosilicon nanoparticles (MON) enclosed by an exterior platelet membrane. PSAB effectively targets CSCs both in vitro and in vivo by P-selectin/CD44 interaction. The degradation of MON and subsequent release of BTS and AIE molecules are facilitated by intracellular glutathione (GSH). Subsequently, the acidic tumor environment triggers the SO2 gas therapy from BTS. This process leads to the depletion of GSH and CSCs elimination. After combining PSAB with photothermal therapy, there is no significant tumor recurrence or metastasis. These results indicate that SO2 gas therapy and AIE-mediated PTT act synergistically to offer a unique approach for preventing tumor recurrence and metastasis after PTT, thus holding significant promise for clinical applications in cancer PTT.
A complex microcapsule formulation comprising epiphyseal plate chondrocytes or other chondrocytes is disclosed. The microcapsule comprises fresh epiphyseal plate chondrocytes or immortalized epiphyseal plate chondrocytes or other chondrocytes, mixed carrier of alginate-collagen-polylysine, sodium citrate as liquefying agent and calcium chloride as solidifying agent. The cell number of the chondrocytes is 2×10 6 ～8×10 6 . The mixed carrier comprises 50-600 parts by weight of alginate, 10-100 part by weight of collagen and 1-10 parts by weight of polylysine. The amount of sodium citrate is 2-20 parts by weight. The amount of calcium chloride is 1-10 parts by weight.
The gut microbiota are mainly composed of Bacteroidetes and Firmicutes and are crucial for metabolism and immunity. Muribaculaceae are a family of bacteria within the order Bacteroidetes. Muribaculaceae produce short-chain fatty acids via endogenous (mucin glycans) and exogenous polysaccharides (dietary fibres). The family exhibits a cross-feeding relationship with probiotics, such as Bifidobacterium and Lactobacillus. The alleviating effects of a plant-based diet on inflammatory bowel disease, obesity, and type 2 diabetes are associated with an increased abundance of Muribaculaceae, a potential probiotic bacterial family. This study reviews the current findings related to Muribaculaceae and systematically introduces their diversity, metabolism, and function. Additionally, the mechanisms of Muribaculaceae in the alleviation of chronic diseases and the limitations in this field of research are introduced.
The invention discloses a kind of oat instant food of nutrition and health care, comprise the following steps：S1. pomelo peel and sugarcane soaking cooking；S2. sprouted unpolished rice boiling；S3. oat is crushed；S4. pomelo peel, sprouted unpolished rice and oat fermentation saccharification, obtain mixing saccharified liquid；S5. black fungus extract solution is prepared；S6. saccharified liquid and black fungus extract solution mixed fermentation are mixed, alcohol fermented beer is made；S7. the acetic acid bacteria culture fluid of volume 6 ~ 8% is accessed in alcohol fermented beer, cavings is added and wheat bran is fermented, obtain fermenting grain；S8. by fermenting grain ageing, squeezing, oat vinegar magma is obtained；S9. required according to finished product vinegar, adjust the acidity of oat vinegar magma, sterilizing is canned, obtains the oat instant food of nutrition and health care.The present invention can be convenient for people to quote, while can also help people's preventing hypertension and alleviate blood pressure rise phenomenon by the way that the raw materials such as pomelo peel, oat, brown rice are brewed into vinegar.
PROBLEM TO BE SOLVED: To obtain the subject new lactic acid bacterium transferred with a sequence created by mutually joining a signal sequence-contg. protein gene, extracellular matrix- binding protein, gene, and anchor sequence gene, and capable of activating the immunological competence, or the like, of a lesion parts without any side effect. SOLUTION: This new lactic acid bacterium is such one as to be transferred with a fused gene sequence created by mutually joining a gene encoding signal sequence- contg. protein, an extracellular matrix-binding protein gene, and a gene encoding anchor sequence, having the ability to bind an extracellular matrix such as fibronectin remarkably exposed on lesion parts such as oncogenesis sites or inflammation sites, and therefore being useful for activating the immunological competence or the like of such lesion parts without any side effect including bacterial infection. The lactic acid bacterium is obtained by mutually joining a signal sequence-contg. protein gene, an extracellular matrix-binding protein gene, and an anchor sequence gene of Lactococcus lactis-derived protease followed by transferring the resultant sequence into lactic acid bacterium.
Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
The current study will investigate the effects of Blood Flow Restriction (BFR) training and L-arginine supplementation on recreationally trained female participants. In particular, it will compare performance outcomes and blood markers among two intervention groups (BFR and BFR+Arg) and a control group (CON). All group will participate in the same training regimen. The control group will train and ingest a placebo pill. The BFR group will train with BFR and ingest a placebo pill, and the BFR+Arg group will train with BFR and ingest an L-arginine pill. All placebo pills will be Maltodextrin. The performance outcome is leg press 1RM, while the blood markers are growth hormone (GH) and cortisol. This analysis will provide insight as to whether or not L-arginine supplementation in addition to blood flow restriction training improves performance and muscle hypertrophy measure more than blood flow restriction training alone.
Participants receive olaparib 300 mg via oral tablet 2 times each day PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 21-day cycle. Participants may receive olaparib+pembrolizumab for up to approximately 2 years.
Primary stroke prevention in non-valvular atrial fibrillation (NVAF) is primarily with non-vitamin K oral anticoagulant (NOAC) therapy. However, 20-36% of ischaemic strokes seem to occur in patients with atrial fibrillation while already on anticoagulation. We present a case of an ischaemic stroke in an elderly female in her 70s with medical history significant for hypertension and NVAF. She had a CHA2DS2-VASc score of 3 and was on apixaban for thromboprophylaxis. She presented with neurological deficits consistent with a left middle cerebral artery stroke, confirmed via head imaging; the most likely stroke aetiology was determined to be cardioembolic in the setting of NVAF. She was treated with continuation of her apixaban at the same dosage She displayed improved function, although with residual expressive aphasia at her 2-month neurology follow-up. Cardioembolic ischaemic stroke in NVAF despite current NOAC therapy does not have current management guidelines.
PROBLEM TO BE SOLVED: To provide genetically-modified donor animals, tissues, and cells.SOLUTION: The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional α1,3 galactosyltransferase (αGT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided. In a particular embodiment, the transgene specifically expressed in pancreatic tissue is at least one anti-coagulant. In another particular embodiment, the transgene specifically expressed in pancreatic tissue is at least one immunomodulator. In specific embodiment, the transgene specifically expressed in pancreatic tissue is at least one immunosuppressant. In a further particular embodiment, the transgene specifically expressed in pancreatic tissue is at least one cytoprotective transgene.SELECTED DRAWING: None
A deodorant composition comprises chlorophyll and one of the following non-volatile germicides or fungicides: a non-volatile fungicidal or germicidal organic quaternary ammonium salt or nuclear substituted diphenylmethane, b -phenoxyethyl alcohol, mono-phenylether of propylene glycol, mono-p-chlorphenylether of ethylene glycol, p-chlor m-xylenol, p-chlor m-cresol, sodium pentachlorphenate or octyl cresol.  A synergistic effect is alleged between the chlorophyll and each of germicides and fungicides specified.  Suitable quaternary ammonium salts are cetyl trimethyl ammonium bromide, di-isobutyl (or p-tertiaryacetyl) phenoxy-ethoxy ammonium bromide, ethyl dimethyl benzyl ammonium chloride and di-isobutylcresoxyethoxy dimethyl benzyl ammonium chloride.  Suitable diphenylmethanes are 2,21-dihydroxy-3,5,6-31,51, 61-hexachlorodiphenzylmethane and 2,21-dihydroxy-5,51-dichlorodiphenylmethane.  The chlorophyll may be oil-, water- or alcohol-soluble and may be a copper, sodium, magnesium, sodium-copper, sodium-iron or sodium-magnesium derivative, e.g. a chlorophyllin.  The composition may be dissolved in a solvent or suspended in a liquid medium, incorporated in a cream for personal application, incorporated with a solid diluent in a dusting powder, or compressed with a water-soluble diluent into a tablet adapted to be dissolved in water.  Other ingredients which may be present include: isopropyl alcohol, mineral oil, white petroleum jelly, calcium or zinc stearate, ethylene glycol laurate, lactose, ammonium sulphate, calcium carbonate and talc.  Specification 617,419 is referred to.
<P>PROBLEM TO BE SOLVED: To provide a method for reducing sliminess of a skin upon rinsing and a tense feeling of the skin after cleaning, and reducing remnant of a cleaning agent containing a surfactant to foods (e.g. vegetables and fruits) and a dish by suppressing adsorption and accumulation of the cleaning agent to the skin, hair, the foods (e.g. vegetables and fruits) and a hard surface of the dish or the like.  <P>SOLUTION: A sophorolipid is used together with the surfactant. The sophorolipid is used as an adsorption suppressing agent of the surfactant, a rinse enhancing agent of cleaning by the surfactant or a tense feeling suppressing agent after cleaning of the skin by the surfactant.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present invention describes calcium sensitive and selective maxi-K potassium channel opener/activator compounds that function to open maxi-K channels under conditions of high intracellular calcium concentrations, and which do not significantly affect the opening of maxi-K channel proteins under conditions of low or physiologically normal intracellular calcium concentrations. Methods of assaying for and using such compounds are also provided. According to the invention, whole cell voltage patch-clamp studies newly demonstrated that the ability of opener compounds, e.g., fluoro-oxindoles and chloro-oxindoles, to open maxi-K channels was sensitive to the intracellular ca2+ concentration ([Ca2+])i, i.e. more channels opened at more negative potentials. Particular fluoro-oxindole and chloro-oxindole compounds produced significant increases in whole-cell maxi-K potassium channel-mediated outward currently only in cells having higher [Ca2+]i, compared with effects in lower [Ca2+]i. Such compounds provide Ca2+-sensitive and selective openers of maxi-K channels which show maximum effectiveness under conditions of increased [Ca2+]i and, as such, provide treatments for diseases and disorders in which cells undergo, or are subject to, traumatic stress due to high internal calcium levels, such as stroke.
OBJECTIVES: Iatrogenic facial nerve palsy following otological surgery is a devastating complication that results in adverse aesthetic and functional outcomes. This study aims to review studies that have reported cases of immediate facial nerve palsy to learn why and where injuries occurred and to assess outcomes following management.
DATABASES REVIEWED: MEDLINE, Embase, Cochrane CENTRAL, and Pubmed up to June 20, 2023.
METHODS: Clinical studies of immediate facial nerve palsies following middle ear and cochlear implantation surgery were included. Risk of bias was examined using the Brazzelli risk of bias tool. Due to the inconsistency in reporting of outcomes, we were unable to perform a meta-analysis.
RESULTS: Of 234 studies identified, 11 met the inclusion criteria. The most common causes of injury were excessive drilling, use of sharp hooks to remove disease, or disorientation of the surgeon secondary to bleeding or inflammation. Variable usage of preoperative computed tomography (CT) imaging and intraoperative facial nerve monitoring was reported. The tympanic segment was the most common site of injury. A variety of surgical techniques were employed to approach the facial nerve injury including facial nerve decompression, direct closure, and repair using an autologous nerve graft.
CONCLUSIONS: Otological surgeons should consider utilizing preoperative CT imaging to establish a three-dimensional mental image of key landmarks and anatomical variations before embarking on surgery. Intraoperative FN monitoring enables safe practice. Despite these measures, complex disease processes and hostile intraoperative conditions can present difficulty. Multiple treatment options are available to treat the underlying injury.
Osteoporosis, a systemic bone disease marked by reduced bone mass and deteriorating bone structure, increases fracture risk, especially in the spine. Vertebral fractures, most common in the lower thoracic and upper lumbar regions, can impair motor function, limit daily activities, and raise disability and mortality risks. With aging, decreasing bone mineral density (BMD) and muscle quality contribute to structural changes like kyphosis and lordosis, further reducing balance and increasing fracture risk. While DEXA remains the standard for BMD assessment, ultrasound (USG) and shear wave elastography (SWE) offer non-invasive imaging for muscle quality without radiation exposure. Despite muscle degeneration's impact on spinal stability, most osteoporosis studies focus on bones, with few examining muscles. Recognizing this gap, our study uses elastography to assess lumbar and abdominal muscle quality and its impact on vertebral fracture risk, while also exploring the relationship between muscle quality, balance, and quality of life in older adults.
PURPOSE: As to the cosmetics for the tint powder including the silk-worm raw silk SAM fine powder, harmful. The risk in which the degree of purity change is less and which lumps or done with the chemical reaction including the oxidization etc. with browning does not have. CONSTITUTION: A cosmetics for the tint powder comprises the silk-worm raw silk SAM fine powder of the total weight comparison 5-20 weight% of the cosmetics for the tint powder. The cosmetics for the tint powder further includes the pigment. The pigment further includes the total weight comparison 0 weight% excess - 5 weight% under of the cosmetics. The cosmetics for the tint powder further comprise the hard magnesium carbonate, kaolin, preservative, pigment, perfume, talc.